The life sciences industry is currently facing unprecedented turmoil. Peter Muller of Schlafender Hase outlines five trends pharma companies will need to weather in 2017, and the considerations needed for smooth adaptation. The life sciences industry is in a state of flux for a whole series of reasons, which can largely be traced back to shifting market dynamics and growing regulatory rigour.
Current Edition
Current Edition
CDMO Subsection
Insights into the latest developments in CDMO services and manufacturing.
Continue readingInjectables Subsection
Expert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingNasal & Pulmonary Subsection
Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue reading
Change Management
